Lumida
/RVNC
⌘K
Revance Therapeutics Inc

Revance Therapeutics Inc

RVNC
$3.65USD+0.27%+0.01 today

MARKET CAP

381.0M

P/E (TTM)

FWD P/E

DAY RANGE

$4 – $4

52W RANGE

$2
$8
STATEMENT·Income statement
USD · GAAP
METRICFY 2019FY 2020FY 2021FY 2022FY 2023TREND
Sales, Adj.$413,000$15.3M$77.8M$132.6M$234.0M
YoY %-88.9%+3610.7%+407.7%+70.4%+76.5%
P / Sales
EV / Sales
Gross Profit, Adj.$413,000$10.6M$54.4M$80.9M$159.7M
YoY %-88.9%+2455.9%+415.2%+48.7%+97.4%
Margin %100.0%68.9%69.9%61.0%68.2%
EV / Gross Profit
EBITDA, Adj.$-161.6M$-262.9M$-254.8M$-233.0M$-209.9M
YoY %-14.6%-62.7%+3.1%+8.6%+9.9%
Margin %-39116.2%-1715.6%-327.5%-175.8%-89.7%
EV / EBITDA
EBIT$-164.5M$-273.2M$-274.7M$-342.0M$-316.8M
YoY %-15.3%-66.1%-0.6%-24.5%+7.4%
Margin %-39820.6%-1782.5%-353.1%-258.0%-135.4%
EV / EBIT
Net Income$-159.4M$-282.1M$-281.3M$-356.4M$-324.0M
YoY %-11.8%-76.9%+0.3%-26.7%+9.1%
Net Margin-38602.7%-1840.7%-361.6%-268.9%-138.4%
EPS (GAAP)-$3.67-$4.86-$4.17-$4.90-$3.83
YoY %+6.9%-32.4%+14.2%-17.5%+21.8%